Avidity Biosciences reports Q2 EPS (66c), consensus (80c)

Reports Q2 revenue $2.3M, consensus $2.14M. “We are executing well across all three of our clinical development programs in three distinct rare muscle diseases – DM1, DMD and FSHD. We plan to report data from each of these clinical programs over the next 12 months,” said Sarah Boyce, president and chief executive officer at Avidity. “With the positive topline data from MARINA(TM) and the easing of the partial clinical hold, we are working to finalize the Phase 3 study design and global regulatory path for AOC 1001 in DM1, while advancing our programs for DMD and FSHD. There are no approved treatment options for these muscle diseases. We are working to bring these much-needed therapies to people as quickly as possible.”